Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
Long-acting injectable ARVs are convenient and private, study participants report

HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling

Published
17 January 2018
By
Roger Pebody
New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose

A new oral device that is taken once a week in a capsule could deliver two or three antiretroviral drugs and significantly reduce the risk

Published
09 January 2018
By
Keith Alcorn
Suboptimal ART adherence associated with greater inflammation in patients with HIV

Recently published findings indicate that suboptimal adherence to ART is associated with activation of coagulation and enhanced residual inflammation among patients with HIV, even if patients have already achieved virologic suppression.

Published
07 January 2018
From
Healio
Fixed-dose regimes ‘modestly’ lower risk of HIV treatment failure

New research compares treatment outcomes of single versus multiple tablet regimes, raising questions around cost-effectiveness.

Published
15 December 2017
From
Avert
Could we safely reduce the frequency of treatments for HIV-positive people?

Most HIV-positive people in France under treatment take a daily dose of antiviral drugs for life. However, a major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

Published
08 December 2017
From
The Conversation
People with HIV more likely to adhere to their antiretroviral therapy than treatment for other chronic health problems

Ageing HIV-positive people have significantly higher levels of adherence to their antiretroviral therapy than to medication taken for other chronic health problems, Swiss investigators report in HIV Medicine. The

Published
07 November 2017
By
Michael Carter
Drug interaction concerns may negatively affect HIV treatment adherence among transgender women

Participants in NIH-supported study apprehensive about combining HIV medications and hormones.

Published
25 July 2017
From
NIAID
Less frequent clinic visits for HIV care: fine tuning needed

Shifts to less frequent clinic visits and medication pick-ups to free up healthcare resources and make life easier for people living with HIV are being implemented successfully

Published
24 July 2017
By
Keith Alcorn
Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks

Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable

Published
24 July 2017
By
Liz Highleyman
HIV drug resistance testing not a priority for resource-limited settings, trial finds

Resistance testing is unlikely to improve the effectiveness of second-line HIV treatment in resource-limited settings and the introduction of routine HIV drug resistance testing is

Published
14 June 2017
By
Keith Alcorn
← First12345...39Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.